Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 1
2012 1
2013 5
2014 4
2016 1
2017 3
2018 5
2019 8
2020 11
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

42 results
Results by year
Filters applied: . Clear all
Page 1
Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy.
Ishida K, Namisaki T, Murata K, Fujimoto Y, Takeda S, Enomoto M, Ogawa H, Takagi H, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Sawada Y, Kitagawa K, Sato S, Nishimura N, Takaya H, Kaji K, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. Ishida K, et al. Among authors: tsuji y. J Clin Med. 2020 Oct 29;9(11):3510. doi: 10.3390/jcm9113510. J Clin Med. 2020. PMID: 33138335 Free PMC article.
Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma.
Takaya H, Namisaki T, Moriya K, Shimozato N, Kaji K, Ogawa H, Ishida K, Tsuji Y, Kaya D, Takagi H, Fujinaga Y, Nishimura N, Sawada Y, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. Takaya H, et al. Among authors: tsuji y. World J Gastroenterol. 2020 Dec 7;26(45):7232-7241. doi: 10.3748/wjg.v26.i45.7232. World J Gastroenterol. 2020. PMID: 33362379 Free PMC article.
Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
Fujinaga Y, Kawaratani H, Kaya D, Tsuji Y, Ozutsumi T, Furukawa M, Kitagawa K, Sato S, Nishimura N, Sawada Y, Takaya H, Kaji K, Shimozato N, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Fujinaga Y, et al. Among authors: tsuji y. Int J Mol Sci. 2020 Aug 4;21(15):5589. doi: 10.3390/ijms21155589. Int J Mol Sci. 2020. PMID: 32759852 Free PMC article.
Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
Ozutsumi T, Namisaki T, Shimozato N, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Nakanishi K, Sato S, Sawada Y, Saikawa S, Kitagawa K, Takaya H, Kawaratani H, Kitade M, Moriya K, Noguchi R, Akahane T, Mitoro A, Yoshiji H. Ozutsumi T, et al. Among authors: tsuji y. Int J Mol Sci. 2020 Mar 21;21(6):2164. doi: 10.3390/ijms21062164. Int J Mol Sci. 2020. PMID: 32245205 Free PMC article.
42 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page